AlzeCure Pharma AB (publ) (ALZCUR.ST)
SEK 2.47
(8.33%)
SEK 2.47
(8.33%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | -2508.00 SEK | -30.08% |
| 2022 | -1928.00 SEK | 21.63% |
| 2021 | -2460.00 SEK | 28.01% |
| 2020 | -3417.00 SEK | -39.58% |
| 2019 | -2448.00 SEK | 99.91% |
| 2018 | -2.61 Million SEK | -49.0% |
| 2017 | -1.75 Million SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | -1.48 Million SEK | 100.0% |
| 2024 Q1 | -3367.00 SEK | -34.25% |
| 2023 Q4 | -2508.00 SEK | -3.13% |
| 2023 Q1 | -3519.00 SEK | -82.52% |
| 2023 FY | -2508.00 SEK | -30.08% |
| 2023 Q2 | -2275.00 SEK | 35.35% |
| 2023 Q3 | -2432.00 SEK | -6.9% |
| 2022 Q4 | -1928.00 SEK | 99.92% |
| 2022 Q3 | -2.3 Million SEK | 6.79% |
| 2022 Q2 | -2.47 Million SEK | 94.91% |
| 2022 Q1 | -48.57 Million SEK | -1874.63% |
| 2022 FY | -1928.00 SEK | 21.63% |
| 2021 Q4 | -2.46 Million SEK | 39.05% |
| 2021 FY | -2460.00 SEK | 28.01% |
| 2021 Q2 | -2.37 Million SEK | 22.24% |
| 2021 Q3 | -4.03 Million SEK | -69.72% |
| 2021 Q1 | -3.05 Million SEK | -38125.0% |
| 2020 FY | -3417.00 SEK | -39.58% |
| 2020 Q4 | -8000.00 SEK | 90.0% |
| 2020 Q1 | -8000.00 SEK | 50.0% |
| 2020 Q2 | -122 Thousand SEK | -1425.0% |
| 2020 Q3 | -80 Thousand SEK | 34.43% |
| 2019 Q4 | -16 Thousand SEK | -54982817869515.81% |
| 2019 Q3 | - SEK | 100.0% |
| 2019 Q2 | -8000.00 SEK | 50.0% |
| 2019 FY | -2448.00 SEK | 99.91% |
| 2019 Q1 | -16 Thousand SEK | -100.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 FY | -2.61 Million SEK | -49.0% |
| 2018 Q4 | -8000.00 SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2017 FY | -1.75 Million SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AcuCort AB | -1.09 Million SEK | 99.772% |
| BioGaia AB (publ) | 181.2 Million SEK | 100.001% |
| Enzymatica AB (publ) | 11.49 Million SEK | 100.022% |
| Enorama Pharma AB (publ) | 4.29 Million SEK | 100.058% |
| Gabather AB (publ) | -1772.00 SEK | -41.535% |
| Klaria Pharma Holding AB (publ.) | - SEK | Infinity% |
| Moberg Pharma AB (publ) | 7.11 Million SEK | 100.035% |
| Nanexa AB (publ) | 1.91 Million SEK | 100.131% |
| Newbury Pharmaceuticals AB (publ) | 4.99 Million SEK | 100.05% |
| ODI Pharma AB | - SEK | Infinity% |
| Orexo AB (publ) | 42.4 Million SEK | 100.006% |
| Probi AB (publ) | 116.7 Million SEK | 100.002% |
| Swedencare AB (publ) | 398.1 Million SEK | 100.001% |
| Swedish Orphan Biovitrum AB (publ) | 3.87 Billion SEK | 100.0% |
| Toleranzia AB | -1.34 Million SEK | 99.813% |
| Vivesto AB | - SEK | Infinity% |